NASDAQ:RGEN - Repligen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$42.21 -0.39 (-0.92 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$42.60
Today's Range$42.13 - $42.59
52-Week Range$29.56 - $46.81
Volume183,200 shs
Average Volume269,749 shs
Market Capitalization$1.86 billion
P/E Ratio61.17
Dividend YieldN/A
Beta0.83

About Repligen (NASDAQ:RGEN)

Repligen logoRepligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111

Debt

Debt-to-Equity Ratio0.17
Current Ratio12.22
Quick Ratio10.25

Price-To-Earnings

Trailing P/E Ratio61.17
Forward P/E Ratio59.45
P/E Growth2.84

Sales & Book Value

Annual Sales$141.24 million
Price / Sales13.06
Cash Flow$0.8572 per share
Price / Cash49.24
Book Value$13.58 per share
Price / Book3.11

Profitability

EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins18.48%
Return on Equity6.06%
Return on Assets4.69%

Miscellaneous

Employees476
Outstanding Shares43,690,000

Repligen (NASDAQ:RGEN) Frequently Asked Questions

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.02. The biotechnology company had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.88 million. Repligen had a net margin of 18.48% and a return on equity of 6.06%. The firm's revenue was up 46.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.15 EPS. View Repligen's Earnings History.

When is Repligen's next earnings date?

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Repligen.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million.

What price target have analysts set for RGEN?

7 Wall Street analysts have issued 12-month price objectives for Repligen's shares. Their predictions range from $40.00 to $50.00. On average, they anticipate Repligen's share price to reach $44.5714 in the next year. View Analyst Ratings for Repligen.

Who are some of Repligen's key competitors?

Who are Repligen's key executives?

Repligen's management team includes the folowing people:
  • Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
  • Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)
  • Mr. Steve Curran, VP of Global Operations
  • Ms. Sondra S. Newman, Sr. Director Investor Relations
  • Mr. Stephen Tingley, VP of Sales

Has Repligen been receiving favorable news coverage?

Media headlines about RGEN stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repligen earned a daily sentiment score of 0.21 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Repligen's major shareholders?

Repligen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), OppenheimerFunds Inc. (4.55%), Dimensional Fund Advisors LP (2.32%), Federated Investors Inc. PA (2.13%), Stephens Investment Management Group LLC (2.13%) and Palisade Capital Management LLC NJ (1.74%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Which major investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Wells Fargo & Company MN, Allianz Asset Management GmbH, Sei Investments Co., Citigroup Inc., RMB Capital Management LLC, Blair William & Co. IL and Schwab Charles Investment Management Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.

Which major investors are buying Repligen stock?

RGEN stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Dimensional Fund Advisors LP, Russell Investments Group Ltd., Federated Investors Inc. PA, UBS Group AG, Pier Capital LLC, Cortina Asset Management LLC and Palisade Capital Management LLC NJ. View Insider Buying and Selling for Repligen.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $42.21.

How big of a company is Repligen?

Repligen has a market capitalization of $1.86 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.

How can I contact Repligen?

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]


MarketBeat Community Rating for Repligen (RGEN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Repligen (NASDAQ:RGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Repligen in the last 12 months. Their average twelve-month price target is $44.5714, suggesting that the stock has a possible upside of 5.59%. The high price target for RGEN is $50.00 and the low price target for RGEN is $40.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.5714$44.5714$44.5714$45.00
Price Target Upside: 5.59% upside28.89% upside28.89% upside29.61% upside

Repligen (NASDAQ:RGEN) Consensus Price Target History

Price Target History for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017CitigroupInitiated CoverageBuy ➝ Buy$45.00MediumView Rating Details
12/5/2017JPMorgan ChaseInitiated CoverageOverweight ➝ Overweight$42.00HighView Rating Details
11/13/2017CL KingInitiated CoverageBuy ➝ Buy$41.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingHold$40.00N/AView Rating Details
10/2/2017First AnalysisUpgradeEqual Weight ➝ Overweight$47.00MediumView Rating Details
9/26/2017StephensReiterated RatingOverweight$50.00HighView Rating Details
7/21/2017William BlairInitiated CoverageOutperform ➝ OutperformLowView Rating Details
6/23/2017Janney Montgomery ScottBoost Price Target$42.00 ➝ $47.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Repligen (NASDAQ:RGEN) Earnings History and Estimates Chart

Earnings by Quarter for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Earnings Estimates

2018 EPS Consensus Estimate: $0.70
2019 EPS Consensus Estimate: $0.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.14$0.16$0.15
Q2 20183$0.19$0.20$0.20
Q3 20183$0.15$0.17$0.16
Q4 20183$0.18$0.20$0.19
Q1 20193$0.17$0.21$0.20
Q2 20192$0.22$0.23$0.23
Q3 20192$0.19$0.21$0.20
Q4 20192$0.21$0.24$0.23

Repligen (NASDAQ RGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018$0.18N/AView Earnings Details
5/8/2018Q1 2018$0.15$0.17$43.88 million$44.80 millionViewN/AView Earnings Details
2/22/2018Q4 2017$0.12$0.20$41.13 million$41.60 millionViewN/AView Earnings Details
11/9/2017Q3 2017$0.11$0.15$35.69 million$36.58 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.1480$0.20$31.72 million$32.40 millionViewListenView Earnings Details
5/4/20173/31/2017$0.13$0.15$29.28 million$30.59 millionViewListenView Earnings Details
2/22/2017Q416$0.07$0.08$24.05 million$25.60 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.07$0.31ViewN/AView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
8/2/2012Q2 2012$0.01$0.05ViewN/AView Earnings Details
5/3/2012Q1 2012$0.04ViewN/AView Earnings Details
3/16/2012Q4 2011($0.04)($0.07)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.02)$0.02ViewN/AView Earnings Details
6/9/2011Q1 2011($0.03)($0.06)ViewN/AView Earnings Details
2/9/2011Q4 2010($0.03)$0.01ViewN/AView Earnings Details
11/2/2010Q3 2010($0.04)$0.02ViewN/AView Earnings Details
8/5/2010Q2 2010$0.03ViewN/AView Earnings Details
6/9/2010Q1 2010($0.05)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.04)($0.01)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.04)($0.03)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.04)($0.04)ViewN/AView Earnings Details
6/11/2009Q1 2009($0.06)($0.09)ViewN/AView Earnings Details
8/7/2008Q2 2008$0.16$0.26ViewN/AView Earnings Details
6/12/2008Q1 2008($0.10)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.05)($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Repligen (NASDAQ:RGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Repligen (NASDAQ RGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 88.22%
Insider Trading History for Repligen (NASDAQ:RGEN)
Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Repligen (NASDAQ RGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Anthony HuntCEOSell16,249$42.53$691,069.97243,144View SEC Filing  
5/16/2018Roy T EddlemanMajor ShareholderSell118,850$42.07$5,000,019.50View SEC Filing  
5/11/2018Karen A DawesDirectorSell20,000$41.80$836,000.00114,957View SEC Filing  
5/9/2018Nicolas BarthelemyDirectorSell26,500$40.54$1,074,310.0027,988View SEC Filing  
5/9/2018Roy T EddlemanMajor ShareholderSell120,000$40.62$4,874,400.00View SEC Filing  
3/8/2018Thomas F Ryan JrDirectorSell4,696$36.16$169,807.369,700View SEC Filing  
1/22/2018Anthony HuntCEOSell8,970$35.95$322,471.5083,613View SEC Filing  
12/14/2017Howard BenjaminVPSell12,729$35.34$449,842.8636,554View SEC Filing  
3/21/2017Karen A DawesDirectorSell2,521$34.12$86,016.5295,764View SEC Filing  
3/20/2017Howard BenjaminVPSell12,216$34.62$422,917.9236,124View SEC Filing  
3/20/2017Thomas F Ryan JrDirectorSell4,000$34.83$139,320.0012,594View SEC Filing  
3/17/2017Jon SnodgresCFOSell1,909$34.91$66,643.1923,789View SEC Filing  
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.0068,342View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.009,394View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.0012,094View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.0027,094View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.0818,626View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Repligen (NASDAQ RGEN) News Headlines

Source:
DateHeadline
Anthony Hunt Sells 16,249 Shares of Repligen (RGEN) StockAnthony Hunt Sells 16,249 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 22 at 7:28 PM
Repligen (RGEN) Rating Increased to Buy at Zacks Investment ResearchRepligen (RGEN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 19 at 10:57 AM
Roy T. Eddleman Sells 118,850 Shares of Repligen (RGEN) StockRoy T. Eddleman Sells 118,850 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 18 at 1:33 PM
Repligen (RGEN) Rating Lowered to Hold at Zacks Investment ResearchRepligen (RGEN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 11:09 AM
Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor ConferenceRepligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
finance.yahoo.com - May 17 at 8:11 AM
Repligen to Participate in 15th Annual Craig-Hallum  Institutional Investor ConferenceRepligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
feeds.benzinga.com - May 17 at 7:49 AM
Q3 2018 EPS Estimates for Repligen Reduced by First Analysis (RGEN)Q3 2018 EPS Estimates for Repligen Reduced by First Analysis (RGEN)
www.americanbankingnews.com - May 16 at 7:24 AM
Repligen (RGEN) Director Sells $836,000.00 in StockRepligen (RGEN) Director Sells $836,000.00 in Stock
www.americanbankingnews.com - May 15 at 10:29 AM
Repligen (RGEN) Rating Increased to Buy at BidaskClubRepligen (RGEN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM
Nicolas Barthelemy Sells 26,500 Shares of Repligen (RGEN) StockNicolas Barthelemy Sells 26,500 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 11 at 1:23 PM
Q4 2018 EPS Estimates for Repligen (RGEN) Cut by Jefferies GroupQ4 2018 EPS Estimates for Repligen (RGEN) Cut by Jefferies Group
www.americanbankingnews.com - May 11 at 10:52 AM
Edited Transcript of RGEN earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of RGEN earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:11 AM
Repligen to Post Q2 2018 Earnings of $0.20 Per Share, Jefferies Group Forecasts (RGEN)Repligen to Post Q2 2018 Earnings of $0.20 Per Share, Jefferies Group Forecasts (RGEN)
www.americanbankingnews.com - May 10 at 6:37 AM
Insider Selling: Repligen (RGEN) Major Shareholder Sells 120,000 Shares of StockInsider Selling: Repligen (RGEN) Major Shareholder Sells 120,000 Shares of Stock
www.americanbankingnews.com - May 9 at 7:15 PM
Novavax (NVAX) & Repligen (RGEN) Head to Head AnalysisNovavax (NVAX) & Repligen (RGEN) Head to Head Analysis
www.americanbankingnews.com - May 8 at 9:09 PM
Repligens (RGEN) CEO Tony Hunt on Q1 2018 Results - Earnings Call TranscriptRepligen's (RGEN) CEO Tony Hunt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:51 PM
Repligen (RGEN) Releases Quarterly  Earnings Results, Beats Estimates By $0.02 EPSRepligen (RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 8 at 2:43 PM
Repligen (RGEN) Updates FY18 Earnings GuidanceRepligen (RGEN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 8:56 AM
Repligen (RGEN) Tops Q1 EPS by 2c, Beats on Revenues; Boosts FY18 EPS/Revenue OutlookRepligen (RGEN) Tops Q1 EPS by 2c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
www.streetinsider.com - May 8 at 8:07 AM
Repligen beats by $0.02, beats on revenueRepligen beats by $0.02, beats on revenue
seekingalpha.com - May 8 at 8:07 AM
Repligen: 1Q Earnings SnapshotRepligen: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:07 AM
Repligen Reports First Quarter 2018 Financial ResultsRepligen Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:07 AM
Zacks: Analysts Anticipate Repligen (RGEN) Will Announce Quarterly Sales of $43.88 MillionZacks: Analysts Anticipate Repligen (RGEN) Will Announce Quarterly Sales of $43.88 Million
www.americanbankingnews.com - May 8 at 1:48 AM
Repligen (RGEN) Given Consensus Recommendation of "Buy" by AnalystsRepligen (RGEN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 3:46 AM
 Analysts Expect Repligen (RGEN) to Announce $0.15 Earnings Per Share Analysts Expect Repligen (RGEN) to Announce $0.15 Earnings Per Share
www.americanbankingnews.com - May 6 at 11:16 PM
Repligen to Report First Quarter 2018 Financial ResultsRepligen to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 5:20 PM
Repligen (RGEN) Upgraded by Zacks Investment Research to "Buy"Repligen (RGEN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 26 at 9:48 AM
Repligen (RGEN) Set to Announce Earnings on ThursdayRepligen (RGEN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM
$43.88 Million in Sales Expected for Repligen (RGEN) This Quarter$43.88 Million in Sales Expected for Repligen (RGEN) This Quarter
www.americanbankingnews.com - April 21 at 1:58 AM
$0.15 EPS Expected for Repligen (RGEN) This Quarter$0.15 EPS Expected for Repligen (RGEN) This Quarter
www.americanbankingnews.com - April 19 at 9:22 PM
Repligen (RGEN) Rating Lowered to Buy at BidaskClubRepligen (RGEN) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM
Repligen (RGEN) Shares Cross Above 200 DMARepligen (RGEN) Shares Cross Above 200 DMA
www.nasdaq.com - April 12 at 5:51 PM
My Investing Horror Story: Selling too EarlyMy Investing Horror Story: Selling too Early
finance.yahoo.com - April 12 at 8:13 AM
Repligen (RGEN) Receives Average Recommendation of "Buy" from AnalystsRepligen (RGEN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 3:52 AM
Repligen (RGEN) Raised to Overweight at First AnalysisRepligen (RGEN) Raised to Overweight at First Analysis
www.americanbankingnews.com - April 8 at 3:17 PM
Repligen Co. (RGEN) Expected to Post Quarterly Sales of $43.88 MillionRepligen Co. (RGEN) Expected to Post Quarterly Sales of $43.88 Million
www.americanbankingnews.com - April 4 at 1:56 AM
Should You Be Tempted To Sell Repligen Corporation (NASDAQ:RGEN) Because Of Its PE Ratio?Should You Be Tempted To Sell Repligen Corporation (NASDAQ:RGEN) Because Of Its PE Ratio?
finance.yahoo.com - April 3 at 5:42 PM
Zacks: Brokerages Anticipate Repligen Co. (RGEN) Will Announce Earnings of $0.15 Per ShareZacks: Brokerages Anticipate Repligen Co. (RGEN) Will Announce Earnings of $0.15 Per Share
www.americanbankingnews.com - April 2 at 11:19 PM
Repligen (RGEN) Stock Rating Lowered by BidaskClubRepligen (RGEN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM
Repligen (RGEN) Upgraded to "Hold" at Zacks Investment ResearchRepligen (RGEN) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:48 PM
Repligen Corporation (NASDAQ:RGEN): Is It A Good Long Term Opportunity?Repligen Corporation (NASDAQ:RGEN): Is It A Good Long Term Opportunity?
finance.yahoo.com - March 27 at 8:16 AM
Repligen (RGEN) Downgraded by BidaskClub to SellRepligen (RGEN) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 25 at 9:50 AM
William Blair Weighs in on Repligen Co.s Q1 2019 Earnings (RGEN)William Blair Weighs in on Repligen Co.'s Q1 2019 Earnings (RGEN)
www.americanbankingnews.com - March 21 at 10:58 AM
Repligen Co. (RGEN) Receives Consensus Rating of "Buy" from BrokeragesRepligen Co. (RGEN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 3:42 AM
 Analysts Anticipate Repligen Co. (RGEN) Will Post Quarterly Sales of $43.88 Million Analysts Anticipate Repligen Co. (RGEN) Will Post Quarterly Sales of $43.88 Million
www.americanbankingnews.com - March 18 at 1:56 AM
Will Repligen Corporation’s (NASDAQ:RGEN) Earnings Grow In The Year Ahead?Will Repligen Corporation’s (NASDAQ:RGEN) Earnings Grow In The Year Ahead?
finance.yahoo.com - March 16 at 6:37 PM
Repligen Co. Expected to Earn FY2020 Earnings of $0.98 Per Share (RGEN)Repligen Co. Expected to Earn FY2020 Earnings of $0.98 Per Share (RGEN)
www.americanbankingnews.com - March 15 at 2:25 PM
Repligen (RGEN) Upgraded by TheStreet to "B-"Repligen (RGEN) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - March 15 at 1:00 PM
William Blair Weighs in on Repligen Co.s Q1 2018 Earnings (RGEN)William Blair Weighs in on Repligen Co.'s Q1 2018 Earnings (RGEN)
www.americanbankingnews.com - March 14 at 7:20 AM
Repligen Co. (RGEN) Director Sells $169,807.36 in StockRepligen Co. (RGEN) Director Sells $169,807.36 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM

SEC Filings

Repligen (NASDAQ:RGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Repligen (NASDAQ:RGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Repligen (NASDAQ RGEN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.